Treats myasthenia gravis. ANDA 208797, held by Rising. Pyridostigmine Bromide.
As of Nov 16, 2026, ANDA 208797 (Pyridostigmine Bromide), held by Rising, was first approved by FDA on Jan 9, 2020, with 0 approved supplements and 0 published complete response letters.
INDICATION Pyridostigmine bromide oral solution USP is useful in the treatment of myasthenia gravis.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 9, 2020 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Pyridostigmine Bromide60MG/5ML · syrup;oral | Pyridostigmine Bromide | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters